,,ib  ,union ,calendar ,no4 #eef  #aaeth
 ,,congress  #b;d ,session  ,h4 ,r4     
#eehb  ,report ,no4 #aae-gba1 ,part ,i  
,,in ,,the ,,house ,,of                 
,,representatives  ,april #bc1 #bjah    
,mr4 ,carter of ,georgia 7for himself1  
,mr4 ,loebsack1 and ,mr4 ,reed7         
introduced the following bill2 which was
 referred to the ,committee on ,energy  
and ,commerce1 and in addition to the   
,committee on ,ways and ,means1 for a   
period to be subsequently determined by 
the ,speaker1 in each case for          
consideration of such provisions as fall
 within the jurisdiction of the         
committee concerned  ,june #h1          
#bjah;,additional sponsors3 ,mr4        
,michael ,f4 ,doyle of ,pennsylvania1   
,mrs4 ,blackburn1 ,mr4 ,walden1 and ,mr4
 ,mc,henry  ,june #h1 #bjah ,reported   
from the ,committee on ,energy and      
,commerce with an amendment ,strike out 
all after the enacting clause and insert
 the part printed in italic  ,june #h1  
#bjah,the ,committee on ,ways and ,means

 discharged2 committed to the ,committee
 of the ,whole ,house on the ,state of  
the ,union and ordered to be printed    
,for text of introduced bill1 see copy  
of bill as introduced on ,april #bc1    
#bjah  ,a ,,bill  ,to direct the        
,secretary of ,health and ,human        
,services to conduct a study and submit 
a report on barriers to accessing       
abuse-deterrent opioid formulations for 
individuals enrolled in a plan under    
part ,c or ,d of the ,medicare program4 
#a4 ,short title ,this ,act may be cited
 at the ,abuse ,deterrent ,access ,act  
of #bjah4  #b4 ,study on abuse-deterrent
 opioid formulations access barriers    
under ,medicare  7a7 ,in general ,not   
later than one year after the date of   
the enactment of this ,act1 the         
,secretary of ,health and ,human        
,services shall conduct a study and     
submit to ,congress a report on the     
adequacy of access to abuse-deterrent   
opioid formulations for individuals with
 chronic pain enrolled in an ,,ma-,,pd  

plan under part ,c of title ,,xviii of  
the ,social ,security ,act or a         
prescription drug plan under part ,d of 
such title of such ,act1 taking into    
account any barriers preventing such    
individuals from accessing such         
formulations under such ,,ma-,,pd or    
part ,d plans1 such as cost-sharing     
tiers1 fail-first requirements1 the     
price of such formulations1 and prior   
authorization requirements4  7b7        
,definition of abuse-deterrent opioid   
formulation ,in this section1 the term  
abuse-deterrent opioid formulation means
 an opioid that is a prodrug or that has
 certain abuse-deterrent properties1    
such as physical or chemical barriers1  
agonist or antagonist combinations1     
aversion properties1 delivery system    
mechanisms1 or other features designed  
to prevent abuse of such opioid4  ,june 
#h1 #bjah,reported from the ,committee  
on ,energy and ,commerce with an        
amendment,june #h1 #bjah ,the ,committee
 on ,ways and ,means discharged2        

committed to the ,committee of the      
,whole ,house on the ,state of the      
,union and ordered to be printed